JPRN-jRCT2080220818未知2 期
Japan/Korea Joint Phase II Study of Nimotuzumab plus Irinotecan in Patients with Advanced or Recurrent Gastric Cancer
DAIICHISANKYO Co.,Ltd.0 个研究点目标入组 80 人开始时间: 2009年8月18日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •Histologically or cytologically confirmed gastric adenocarcinoma.
- •Unresectable or recurrent gastric cancer patients, refractory to 5-fluorouracil-based agents or 5-fluorouracil-containing therapy. Only one prior regimen is eligible.
- •ECOG Performance Status is 0-1
排除标准
- •Patients who previously received irinotecan
- •Patients who previously received EGFR-directed therapy (e.g. cetuximab, erlotinib).
- •Patients with any of the following severe or uncontrolled intercurrent diseases
研究者
相似试验
终止
3 期
Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction CancerGastroesophageal Junction CancerGastric CancerNCT01813253Kuhnil Pharmaceutical Co., Ltd.400
未知
2 期
Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma PatientsMelanomaJPRN-jRCT2080222335Bristol-Myers K.K.18
未知
2 期
A Phase II Study of Nimotuzumab in Patients with Unresectable Stage III Non-small Cell Lung Cancernresectable stage III non-small cell lung cancerJPRN-jRCT2080220796DAIICHISANKYO Co.,Ltd.39
已完成
2 期
Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung CancerNon-small-cell Lung CancerNCT02577341Sun Yat-sen University122
终止
1 期
A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung CancerNon-small-cell Lung CancerNCT00369447YM BioSciences52